BACKGROUND: Elevated levels of fibroblast growth factor 23 (FGF23) are associated with incident heart failure in individuals with or without chronic kidney disease. We aimed to investigate the association between serum FGF23 concentrations and disease severity and long-term outcome in patients with stable heart failure. MATERIALS AND METHODS: Serum levels of C-term FGF23 (Ct-FGF23) concentrations, inorganic phosphate (Pi ), parathormone (PTH) and 25-hydroxyvitamin D (25(OH)D) were measured in 208 patients with nonischaemic heart failure (age 48 ± 15 years; 70% male; NYHA Class I 27·8%, NYHA Class II 43·4%, NYHA Class III/IV 28·8%; LV-EF 34 ± 15%; eGFR ≥60 mL/min/1·73 m(2) in 86%). RESULTS: Median Ct-FGF23 levels were 18·2 RU/mL (7·5-40·8RU/mL). A dose-response relationship was found between median Ct-FGF23 levels and increasing NYHA class (I: 11·9 RU/mL, II: 15·8 RU/mL, III/IV: 38·8 RU/mL; P < 0·001). Ct-FGF23 correlated with NTproBNP (r = 0·307, P < 0·001), central venous pressure, mean pulmonary arterial pressure, pulmonary capillary wedge pressure and inversely correlated with cardiac output after adjustment for renal function (eGFR) and Pi . LnCt-FGF23 was related with the combined endpoint of death or heart transplantation (hazard ratio 1·452 [1·029-2·048]; P = 0·034) independent of Pi , PTH, 25(OH)D, age and sex. CONCLUSION: The phosphatonin FGF23 is strongly associated with disease severity and long-term outcome in patients with nonischaemic heart failure and preserved renal function. Further studies are needed to evaluate the pathophysiologic role of FGF23 and its potential as a biomarker in heart failure.
BACKGROUND: Elevated levels of fibroblast growth factor 23 (FGF23) are associated with incident heart failure in individuals with or without chronic kidney disease. We aimed to investigate the association between serum FGF23 concentrations and disease severity and long-term outcome in patients with stable heart failure. MATERIALS AND METHODS: Serum levels of C-term FGF23 (Ct-FGF23) concentrations, inorganic phosphate (Pi ), parathormone (PTH) and 25-hydroxyvitamin D (25(OH)D) were measured in 208 patients with nonischaemic heart failure (age 48 ± 15 years; 70% male; NYHA Class I 27·8%, NYHA Class II 43·4%, NYHA Class III/IV 28·8%; LV-EF 34 ± 15%; eGFR ≥60 mL/min/1·73 m(2) in 86%). RESULTS: Median Ct-FGF23 levels were 18·2 RU/mL (7·5-40·8RU/mL). A dose-response relationship was found between median Ct-FGF23 levels and increasing NYHA class (I: 11·9 RU/mL, II: 15·8 RU/mL, III/IV: 38·8 RU/mL; P < 0·001). Ct-FGF23 correlated with NTproBNP (r = 0·307, P < 0·001), central venous pressure, mean pulmonary arterial pressure, pulmonary capillary wedge pressure and inversely correlated with cardiac output after adjustment for renal function (eGFR) and Pi . LnCt-FGF23 was related with the combined endpoint of death or heart transplantation (hazard ratio 1·452 [1·029-2·048]; P = 0·034) independent of Pi , PTH, 25(OH)D, age and sex. CONCLUSION: The phosphatonin FGF23 is strongly associated with disease severity and long-term outcome in patients with nonischaemic heart failure and preserved renal function. Further studies are needed to evaluate the pathophysiologic role of FGF23 and its potential as a biomarker in heart failure.
Authors: Rupal Mehta; Xuan Cai; Jungwha Lee; Julia J Scialla; Nisha Bansal; James H Sondheimer; Jing Chen; L Lee Hamm; Ana C Ricardo; Sankar D Navaneethan; Rajat Deo; Mahboob Rahman; Harold I Feldman; Alan S Go; Tamara Isakova; Myles Wolf Journal: JAMA Cardiol Date: 2016-08-01 Impact factor: 14.676
Authors: Daniel Edmonston; Daniel Wojdyla; Rupal Mehta; Xuan Cai; Claudia Lora; Debbie Cohen; Raymond R Townsend; Jiang He; Alan S Go; John Kusek; Matthew R Weir; Tamara Isakova; Michael Pencina; Myles Wolf Journal: Am J Kidney Dis Date: 2019-08-21 Impact factor: 8.860
Authors: Jonathan P Law; Luke Pickup; Davor Pavlovic; Jonathan N Townend; Charles J Ferro Journal: J Hum Hypertens Date: 2022-09-22 Impact factor: 2.877
Authors: G Poelzl; S K Ghadge; M Messner; B Haubner; Ph Wuertinger; A Griesmacher; J Doerler; C Ensinger; H Ulmer; M M Zaruba Journal: Sci Rep Date: 2018-05-30 Impact factor: 4.379
Authors: Mark Luedde; Sanchari Roy; Hans-Joerg Hippe; David Vargas Cardenas; Martina Spehlmann; Mihael Vucur; Pia Hoening; Sven Loosen; Norbert Frey; Christian Trautwein; Tom Luedde; Alexander Koch; Frank Tacke; Christoph Roderburg Journal: Sci Rep Date: 2018-06-27 Impact factor: 4.379
Authors: Michele F Eisenga; Mireille E Emans; Karien van der Putten; Maarten J Cramer; Adry Diepenbroek; Birgitta K Velthuis; Pieter A Doevendans; Marianne C Verhaar; Jaap A Joles; Stephan J L Bakker; Ilja M Nolte; Branko Braam; Carlo A J M Gaillard Journal: J Am Heart Assoc Date: 2019-08-17 Impact factor: 5.501